Near future
No Result
View All Result
25 September 2023
  • Home
  • Tech
  • Health
  • Environment
  • Energy
  • Transports
  • Spazio
  • AI
  • concepts
  • H+
Understand, anticipate, improve the future.
CES2023 / Coronavirus / Russia-Ukraine
Near future
  • Home
  • Tech
  • Health
  • Environment
  • Energy
  • Transports
  • Spazio
  • AI
  • concepts
  • H+

Understand, anticipate, improve the future.

No Result
View All Result
Medicine

A nano-drug precisely attacks chemotherapy-resistant cancer

A single nanoparticle works in two ways: it increases the effectiveness of chemotherapy and acts as a stimulant of the immune system.

April 20 2022
Gianluca RiccioGianluca Riccio
⚪ 2 minutes
Share489Pin111Tweet306SendShare86ShareShare61
POST FP 700X500 2022 04 20T173558.777

READ IN:

In a study published in Advanced Materials magazine, Tel Aviv University (TAU) scientists have demonstrated the efficacy of a cancer therapy that can overcome both chemotherapy and resistance to immunotherapy.

At the head of the research (joint with South Korean colleagues) the Prof Dan Peer, vice president of TAU and head of the precision nanomedicine laboratory.

cancer chemotherapy drug
Illustration of the anticancer nanopharmaceutical at work. (credits: TEL AVIV UNIVERSITY)

Get over chemotherapy

Chemo-immunotherapy, a combination of chemotherapy and immunotherapy, could become the most advanced standard of care for various types of cancer. "This is the first time that a single drug derived from a nanoparticle with RNA has been used in humans," explains Prof. Peer. "This is just the beginning of this research, but it holds significant promise in the fight against cancer."

The two types of therapy work together; there chemotherapy kills cancer cells while theimmunotherapy it stimulates the patient's immune system to attack the cancer on its own.

The article continues after the related links

From the laboratory to life: here are the bacteria that "see" tumor DNA

TAU University, bacterial toxin causes cancer cells to "suicide".

A difficult challenge

Unfortunately, many patients respond poorly to this dual treatment because its goals are not specific enough.

Cancers resistant to chemotherapy are a serious problem. The researchers targeted an enzyme called HO1, which is responsible for resistance to therapy. Identifying the "killer", however, is not the same as killing him. Current strategies for silencing HO1, in particular, are too strong for patients' bodies. Dr. Peer compares them to a fighter jet used to hit an ant.

dan peer chemotherapy
Professor Dan Peer of Tel Aviv University (credit: TEL AVIV UNIVERSITY)

The TAU team was the first to demonstrate that a drug delivery system based on lipid nanoparticles (the same used for RNA vaccines "deployed" against Covid) can target extremely particular cells: cancer cells for chemotherapy and immune cells for immunotherapy.

From this new research may come the results we hope against the cancer, even the most resistant one.

Tags: cancerRNA

Latest news

  • Tesla and the new abilities of Optimus robots: "Ready for mass production"
  • EV, goodbye frequent charging: I-State promises over 1.000 km of autonomy.
  • Revolutionary generator transforms humidity into continuous electrical energy
  • All the maps of the future: from research tools to doors to tomorrow
  • The bizarre AI that translates the language of chickens
  • Jeddah Tower, construction site of the one kilometer high skyscraper reopens
  • Spider silk from modified silkworms: stronger than Kevlar and 100% natural
  • VIR-1388, HIV vaccine being tested in the USA and South Africa
  • MOWT, innovative floating hydroelectric for slow-flowing waters
  • CRAFT, what stage is the Chinese project to build an artificial Sun?


GPT Chat Megaeasy!

Concrete guide for those approaching this artificial intelligence tool, also designed for the school world: many examples of applications, usage indications and ready-to-use instructions for training and interrogating Chat GPT.

To submit articles, disclose the results of a research or scientific discoveries write to the editorial staff

Enter the Telegram channel of Futuroprossimo, click here. Or follow us on Instagram, Facebook, Twitter, Mastodon e LinkedIn.

FacebookTwitterInstagramTelegramLinkedInMastodonPinterestTikTok

The daily tomorrow.


Futuroprossimo.it provides news on the future of technology, science and innovation: if there is something that is about to arrive, here it has already arrived. FuturoProssimo is part of the network ForwardTo, studies and skills for future scenarios.

  • Environment
  • Architecture
  • Artificial intelligence
  • Gadgets
  • concepts
  • Design
  • Medicine
  • Spazio
  • Robotica
  • Work
  • Transports
  • Energy
  • Edition Francaise
  • Deutsche Ausgabe
  • Japanese version
  • English Edition
  • Portuguese Edition
  • Read more
  • Spanish edition

Subscribe to our newsletter

  • The Editor
  • Advertising on FP
  • Privacy Policy

© 2023 Near future - Creative Commons License
This work is distributed under license Creative Commons Attribution 4.0 International.

No Result
View All Result
Understand, anticipate, improve the future.
  • Home
  • Tech
  • Health
  • Environment
  • Energy
  • Transports
  • Spazio
  • AI
  • concepts
  • H+